Kwong Lung Enterprise Bilan de santé

Santé financière contrôle des critères 6/6

Kwong Lung Enterprise possède un total de capitaux propres de NT$5.9B et une dette totale de NT$2.2B, ce qui porte son ratio d'endettement à 37.3%. Son actif total et son passif total sont NT$9.6B et de NT$3.8B. L'EBIT de Kwong Lung Enterprise est NT$557.9M ce qui fait que son ratio de couverture des intérêts -20.3. Elle dispose de liquidités et de placements à court terme de NT$963.2M.

Informations clés

37.3%

Ratio d'endettement

NT$2.19b

Dette

Ratio de couverture des intérêts	-20.3x
Argent liquide	NT$963.19m
Fonds propres	NT$5.87b
Total du passif	NT$3.77b
Total des actifs	NT$9.64b

Mises à jour récentes de la santé financière

Kwong Lung Enterprise (GTSM:8916) Seems To Use Debt Quite Sensibly

Jan 22

Recent updates

Kwong Lung Enterprise (GTSM:8916) Will Be Hoping To Turn Its Returns On Capital Around

Apr 02

Are Dividend Investors Making A Mistake With Kwong Lung Enterprise Co., Ltd. (GTSM:8916)?

Feb 25

Kwong Lung Enterprise (GTSM:8916) Seems To Use Debt Quite Sensibly

Jan 22

We're Watching These Trends At Kwong Lung Enterprise (GTSM:8916)

Dec 31

Kwong Lung Enterprise Co., Ltd. (GTSM:8916) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?

Dec 17

How Much Is Kwong Lung Enterprise Co., Ltd. (GTSM:8916) CEO Getting Paid?

Nov 25

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de 8916 ( NT$4.4B ) dépassent ses passifs à court terme ( NT$3.0B ).

Passif à long terme: Les actifs à court terme de 8916 ( NT$4.4B ) dépassent ses passifs à long terme ( NT$759.5M ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: Le ratio dette nette/capitaux propres de 8916 ( 20.9% ) est considéré comme satisfaisant.

Réduire la dette: Le ratio d'endettement de 8916 a été réduit de 37.8% à 37.3% au cours des 5 dernières années.

Couverture de la dette: La dette de 8916 est bien couverte par le flux de trésorerie opérationnel ( 36.4% ).

Couverture des intérêts: 8916 gagne plus d'intérêts qu'il n'en paie, donc la couverture des paiements d'intérêts n'est pas un problème.

Kwong Lung Enterprise Bilan de santé

Santé financière contrôle des critères 6/6

Informations clés

Mises à jour récentes de la santé financière

Kwong Lung Enterprise (GTSM:8916) Seems To Use Debt Quite Sensibly

Recent updates

Third quarter 2024 earnings released: EPS: NT$0.91 (vs NT$1.44 in 3Q 2023)

Second quarter 2024 earnings released: EPS: NT$1.64 (vs NT$1.87 in 2Q 2023)

Now 21% overvalued

Kwong Lung Enterprise Co., Ltd. to Report Q2, 2024 Results on Aug 08, 2024

Upcoming dividend of NT$3.58 per share

Kwong Lung Enterprise Co., Ltd. Approves Cash Dividend on Common Shares, Payable on August 21, 2024

First quarter 2024 earnings released: EPS: NT$0.98 (vs NT$0.53 in 1Q 2023)

New minor risk - Shareholder dilution

Kwong Lung Enterprise Co., Ltd. to Report Q1, 2024 Results on May 09, 2024

Full year 2023 earnings released: EPS: NT$3.93 (vs NT$6.54 in FY 2022)

Kwong Lung Enterprise Co., Ltd., Annual General Meeting, May 31, 2024

Kwong Lung Enterprise Co., Ltd.'S Board of Directors Resolves to Establish A Risk Management Committee

Third quarter 2023 earnings released: EPS: NT$1.44 (vs NT$2.78 in 3Q 2022)

Kwong Lung Enterprise Co., Ltd. Announces Change of Corporate Governance Officer

New minor risk - Shareholder dilution

Second quarter 2023 earnings released: EPS: NT$1.68 (vs NT$1.89 in 2Q 2022)

Upcoming dividend of NT$3.79 per share at 7.2% yield

Price target decreased by 11% to NT$62.00

Kwong Lung Enterprise Co., Ltd. Approves Dividend on Common Share, Payable on August 31, 2023

Full year 2022 earnings released: EPS: NT$6.54 (vs NT$3.58 in FY 2021)

Price target increased to NT$67.00

Third quarter 2022 earnings released: EPS: NT$2.78 (vs NT$0.26 loss in 3Q 2021)

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: NT$1.89 (vs NT$1.00 in 2Q 2021)

Upcoming dividend of NT$3.00 per share

Kwong Lung Enterprise Co., Ltd. Announces Common Share Cash Dividend, Payable on August 19, 2022

First quarter 2022 earnings released: EPS: NT$1.11 (vs NT$0.98 in 1Q 2021)

Less than half of directors are independent

Full year 2021 earnings released: EPS: NT$3.58 (vs NT$2.28 in FY 2020)

Third quarter 2021 earnings released: NT$0.26 loss per share (vs NT$0.98 profit in 3Q 2020)

Price target decreased to NT$40.00

Less than half of directors are independent

Less than half of directors are independent

First quarter 2021 earnings released: EPS NT$0.98 (vs NT$0.17 in 1Q 2020)

Representative Director has left the company

Full year 2020 earnings released: EPS NT$2.28 (vs NT$4.10 in FY 2019)

Kwong Lung Enterprise (GTSM:8916) Will Be Hoping To Turn Its Returns On Capital Around

Full year 2020 earnings released: EPS NT$2.28 (vs NT$4.10 in FY 2019)

Kwong Lung Enterprise Co., Ltd., Annual General Meeting, May 31, 2021

New 90-day high: NT$40.35

Are Dividend Investors Making A Mistake With Kwong Lung Enterprise Co., Ltd. (GTSM:8916)?

Kwong Lung Enterprise (GTSM:8916) Seems To Use Debt Quite Sensibly

New 90-day low: NT$38.50

We're Watching These Trends At Kwong Lung Enterprise (GTSM:8916)

Kwong Lung Enterprise Co., Ltd. (GTSM:8916) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?

New 90-day low: NT$39.25

How Much Is Kwong Lung Enterprise Co., Ltd. (GTSM:8916) CEO Getting Paid?

Kwong Lung Enterprise Announces Executive Changes, Effective November 09, 2020

Third quarter 2020 earnings released: EPS NT$0.98

Revenue misses expectations

New 90-day low - NT$40.30

First half earnings released

First half earnings released

Analyse de la situation financière

Historique et analyse du ratio d'endettement

Bilan

Découvrir des entreprises saines